Chief Executive Officer
Colin Broom joined Nabriva Therapeutics in August 2014. He has a bachelor of science degree in pharmacology from University College, London and a bachelor of medicine and surgery degree from St. George’s Hospital Medical School, London. He is a Member of the UK Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine. Over the past 30 years Colin has been involved in all stages of drug development and commercialization. Most recently, he served as Chief Scientific Officer at ViroPharma, Inc., (now Shire). Previous positions have included a range of leadership positions with Amgen, Hoechst Marion Roussel (now Sanofi), SmithKline Beecham and Glaxo (now GlaxoSmithKline).
Robert Crotty joined Nabriva in June 2017. Mr. Crotty joins Nabriva with over a decade of experience in the pharmaceutical and biopharmaceutical industries, most recently as VP, General Counsel, Chief Compliance Officer and Secretary at Vernalis Therapeutics, Inc. Mr. Crotty has a broad legal skill set with experience in corporate governance, securities filings, financing, business development, corporate law and commercial compliance. Previously, Mr. Crotty worked in the life sciences industry with positions at Dendreon Corporation, NPS Pharmaceuticals and ImClone Systems Incorporated. After law school, he worked at two law firms, Morgan, Lewis & Bockius and Norton Rose Fulbright. Mr. Crotty obtained his law degree from the University of Pennsylvania and his undergraduate degree from Princeton University.
Chief Scientific Officer and Head of Business Development
Steven Gelone joined Nabriva Therapeutics in December 2014. He has a bachelor of sciences and doctorate in pharmacy degree from Temple University in Philadelphia. Over the past 20 years Steve has been involved in all stages of drug development and commercialization. He has served as Head of Clinical Research and Development at Spark Therapeutics, as well as Vice President of Development at ViroPharma Incorporated (now Shire). Previous roles include a leadership positions with GSK, Vicuron Pharmaceuticals and Temple University Schools of Pharmacy and Medicine.
Chief Commercial Officer
Francesco Maria Lavino joined Nabriva Therapeutics in July 2017 bringing nearly two decades of pharmaceutical sales and marketing experience. The last half of his career has been focused on anti-infective medications administered primarily in the hospital setting. He most recently served as AVP, Global Brand Leader Anti-Infective Portfolio at Merck & Co. Inc. (known as MSD outside the United States), where he was responsible for the development and implementation of the global marketing strategy for the whole Merck anti-bacterial portfolio. Prior to this role, Francesco was VP International Marketing for the Anti-Infectives Portfolio at Cubist Pharmaceuticals and previous roles at Merck included global brand leadership for the company’s antifungal portfolio and, before, he held positions in marketing and sales both at regional and country level. Francesco began his career in pharmaceutical sales at UCB Pharma and 3M in Italy. He has a Bachelor of Arts in Pharmacy from the Federico II University of Napoli, Italy and an MBA from SDA Bocconi School of Management in Milan, Italy
Chief Medical Officer
Elyse Seltzer joined Nabriva Therapeutics in May 2015. She has a bachelor of arts from the University of Pennsylvania and a medical degree from New York University School of Medicine. She completed her Internal Medicine training at the University of Pennsylvania Medical Center, and her Infectious Diseases training at Yale New Haven Hospital. Since 1999, Elyse has been involved in all stages of drug development and commercialization. Most recently she served as Vice President, Global Clinical Sciences and Operations at GlaxoSmithKline. Previously she was Chief Medical Officer at Tengion, and has held leadership positons at Centocor, Vicuron, where she led the development of dalbavancin and at SmithKline Beecham.
Chief Financial Officer
Gary Sender has over 25 years of financial leadership experience in the pharmaceutical and biopharmaceutical industries, most recently as Chief Financial Officer and EVP at Synergy Pharmaceuticals. From 2009-2015, Mr. Sender served as Senior Vice President, Finance at Shire plc. supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. He was responsible for financial management and support of all commercial areas of Shire’s $6 billion Specialty Pharmaceutical and Rare Disease businesses, with an emphasis on resource allocation, financial forecasting, business cases and M&A. Prior to joining Shire, he was the founding CFO of Tengion – a biotechnology company in the field of Regenerative Medicine. Mr. Sender spent 15 years in a number of leadership roles within Merck, including Investor Relations, M&A Finance, Treasury and Divisional Financial Management. Mr. Sender holds a bachelor’s degree in Finance and Information Systems from Boston University and a master’s degree in Industrial Administration (MBA) with a concentration in Finance from Carnegie-Mellon University.
Vice President, Corporate Controller and Head of Investor Relations
Dave joined Nabriva in November 2015. He held previous finance roles with Covis Pharma, Auxilium, Shire and ViroPharma. Dave started his career in public accounting with KPMG and is a Certified Public Accountant. Dave received his Bachelor of Science and Master of Business Administration degrees from Villanova University. He is a member of the FEI, AICPA and PICPA.
Vice President, Clinical Research and Development
Leanne Gasink joined Nabriva Therapeutics in November 2015. She has a bachelor of science from the Pennsylvania State University and a medical degree and masters of science in clinical epidemiology from the University of Pennsylvania. She completed her Internal Medicine and Infectious Diseases training at the University of Pennsylvania. Prior to joining the biopharmaceutical industry, Leanne was the Associate Hospital Epidemiologist and Co-Director of the Antimicrobial Stewardship Program at the Hospital of the University of Pennsylvania. Since 2009, she has focused on the development of treatments for infections due to multi-drug resistant bacteria. She previously held positions at AstraZeneca, where she played a leadership role in the late stage development and subsequent approval of Ceftazadime-avibactam.
Vice President CMC & IP
Werner Heilmayer joined Nabriva Therapeutics in February 2006. He holds a PhD in organic chemistry. Having worked for almost 20 years in the pharmaceutical and biotech industry, Werner has gained significant experience in drug development and intellectual property. He has a strong track record in patent filing and is co-inventor of more than 10 international filed patent applications. Before joining Nabriva Werner held the position of Head of Chemistry of Sandoz's discovery unit. Werner played a major role in the Nabriva spin-off from Sandoz and served Nabriva as Head CMC and IP before he was appointed VP CMC & IP in June 2012.
Vice President Quality
Ernest Kelly joined Nabriva Therapeutics full time in June 2016. He has a bachelor of arts degree in Chemistry from Millersville University and a Ph.D. in Physical Chemistry from Villanova University. Over the past 44 years Ernie has been involved in all stages of pharmaceutical development and commercialization, most recently as Vice President, Quality at Shire plc. Previous roles include leadership and technical positions in Quality and Compliance with ViroPharma (now Shire), Cephalon, Bio-Technology General Corp, Rhone Poulenc Rorer (now Sanofi), Merck and McNeil pharmaceutical companies. Ernie has been active in pharmaceutical trade associations and is a past chair of several PhRMA Technical Committees, past industry representative on USP Aerosol Advisory Panels and a past Adjunct Professor of Pharmaceuticals, Temple University, School of Pharmacy.
Chief Information Officer
Thomas Lembck joined Nabriva Therapeutics full time in July 2015. For 13 years, he led the IT and Facility teams at ViroPharma Incorporated building a global organization to support the rapid growth of the organization and supported the company’s acquisition transition into Shire plc. Prior to Viropharma, he worked with VisAlign, where he led various teams and projects focused on information systems and strategic planning for pharmaceutical companies including Schering-Plough, Pfizer, and Merck. Thomas also has held multiple roles of escalating responsibility at Comptek Research, Raytheon, and ABB in Zurich, Switzerland. At Nabriva, he has demonstrated technology leadership by crafting the requisite strategic vision to achieve business goals by offering a unique blend of executive acumen, global team-building and IT solutions development with strong ROI and operational effectiveness. Thomas holds a master of business administration degree from Temple University, a bachelor of science degree from Rensselaer Polytechnic Institute in Electrical Engineering, and several executive training certificates from both the Bell Leadership program at University of North Carolina and Dartmouth’s Tuck Business School.
Vice President Commercial Strategy
Will Sargent joined Nabriva September 2015. Mr. Sargent joins Nabriva with over two decades of experience in the biopharmaceutical industry, including leadership roles for multiple product and line extension launches and as a sell-side analyst on Wall Street. Most recently, he served as Vice President, Orthopedic Business Unit at Auxilium Pharmaceuticals (now ENDO International) where he led the company's marketing and sales team advancing XIAFLEX® for the treatment of Dupuytren's contracture and development of additional pipeline indications. Mr. Sargent received his Bachelor of Arts in Biology from Johns Hopkins University and an MBA from the University of Washington